GH1 and pituitary gland adenoma: Management is targeted at relief of the patient's symptoms; reduction in the bulk of the pituitary adenoma when there are mass-related symptoms; optimizing biochemical markers of disease activity (GH and IGF-I ); and reversal or prevention of progression of associated long-term complications and mortality.3,4 Strict control of GH levels to <1.0 μg/L in association with a normal age-adjusted IGF-I level has been shown to normalize mortality to that of the background population as well as slow progression, or even reverse some of the associated long-term complications.2